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Abstract: A total of 14 novel arylpiperazines were synthesized, and pharmaco-
logically evaluated by measuring their affinities towards the D2 dopamine receptor 
(DRD2) in a [3H]spiperone competition assay. All the herein described compounds 
consist of a benzimidazole moiety connected to N-(2-methoxyphenyl)piperazine 
via linkers of various lengths. Molecular docking analysis and molecular dynamics 
simulations were performed on the DRD2–arylpiperazine complexes with the 
objective of exploring the receptor–ligand interactions and properties of the rec-
eptor binding site. The recently published crystal structure of DRD2 was used 
throughout this study. The major finding is that high affinity arylpiperazines must 
interact with both the orthosteric binding site and the extended binding pocket of 
DRD2 and therefore should contain a linker of 5 or 6 methylene groups long. 
Keywords: arylpiperazines; molecular dynamics; molecular docking; receptor 
binding site. 
INTRODUCTION 
Dopamine receptors belong to the rhodopsin-like, aminergic G protein- 
-coupled receptors (GPCRs) group. They are involved in many physiological 
processes and play important role in the central nervous system (CNS).1–4  
Targeting the dopamine D2 receptors (DRD2) is a common strategy for the 
treatment of neurodegenerative diseases, such as schizophrenia, Parkinson’s 
disease, dementia and depression.5–8 
It is a well-documented fact that N-substituted arylpiperazines are com-
pounds with pronounced DRD2 activity.9,10 Since arylpiperazines have a wide 
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spectrum of therapeutic potentials and the design, synthesis and characterization 
of new arylpiperazine like drugs is an ever growing field of research.11–14  
In this paper, the synthesis of 14 new N-(2-methoxyphenyl)piperazines of 
the general structure 5 (Scheme 1) is presented. Their affinities towards DRD2 
were evaluated in the [3H]spiperone competition assay. 
Recent discovery of DRD2 crystal structure with bound risperidone15 def-
ined the receptor binding site with greater accuracy than existing homology 
models. This finding prompted us to investigate DRD2–arylpiperazine binding 
features, using molecular docking analysis and molecular dynamics simulations 
in order to define key receptor–ligand interactions and explain the dopaminergic 
properties of the herein described compounds. 
EXPERIMENTAL 
The reagents and solvents used in this work were obtained from Alfa–Aesar or Sigma– 
–Aldrich and used without further purification. Solvents were routinely dried over anhydrous 
Na2SO4 prior to evaporation. 
General 
A Boetius PHMK apparatus (VEB Analytic, Dresden, Germany) was used to determine 
the melting points, which are here presented uncorrected. The 1H-NMR and 13C-NMR spectra 
were recorded at 200 and 50 MHz, respectively, on a Gemini 2000 (Varian, Oxford). The 
spectra were recorded in deuterochloroform with tetramethylsilane as the internal standard; 
the chemical shifts (δ) are reported in parts per million (ppm); all coupling constants (J 
values) are reported in Hz. LC/MS was performed on a 6210 time-of-flight LC–MS system 
(Agilent Technologies, Germany). For data analysis, MassHunter workstation software was 
used. The infrared (IR) spectra were obtained on a Thermo Scientific spectrometer. For ana-
lytical thin-layer chromatography (TLC), Polygram SIL G/UV254 plastic-backed thin layer 
silica gel plates were used (Macherey–Nagel, Germany). The chromatographic purifications 
were performed on Merck-60 silica gel columns (230–400 mesh ASTM) under medium pres-
sure (dry column flash chromatography). Analytical and spectral data for the synthesized 
compounds are given in Supplementary material to this paper. A MicroSYNTH Milestone and 
a Biotage Initiator 2.5 EXP were used for the microwave experiments. 
Chemistry 
General procedure for the synthesis of compounds 3a–g. A suspension of 1-(2-methoxy-
phenyl)piperazine (1, 0.084 mol), triethylamine (0.0874 mol), K2CO3 (0.175 mol) and bromo-
ester 2a–g (0.084 mol) in 2-butanone (100 mL) was stirred for 24 h at 80 °C. After cooling, 
the mixture was poured into cold water and the organic layer was extracted with CH2Cl2 and 
concentrated in vacuo. The resulting ester was purified by silica gel column chromatography 
using a gradient of methanol (0–5 %) in dichloromethane. 
General procedure for the synthesis of compounds 5a–n. Compounds 3a–g (0.0035 mol) 
and diamines 4a–c (0.0035 mol) were suspended in 8 mL 50 % methanesulfonic acid in water, 
transferred into a sealed tube, and microwave irradiated at 180 °C for 45 min at 300 W. After 
cooling to room temperature, the reaction mixture was poured into ice-cold water and 
neutralized with a saturated solution of NaOH. The product was extracted with CH2Cl2 and 
concentrated in vacuo. The resulting 1H-benzimidazoles were purified by silica gel column 
chromatography using a gradient of methanol (0–5 %) in dichloromethane.  
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Biological assays 
Membrane preparation. Rat caudate nuclei synaptosomal membranes for the DRD2 
binding experiments were prepared as previously described.16 Striatal tissue acquired from 
male Wistar rats (150–200 g) was used as the source of DRD2. The tissue was homogenized 
in 20 volumes of ice-cold 50 mM Tris-HCl buffer containing 120 mM NaCl, 5 mM KCl, 1 
mM MgCl2 and 2 mM CaCl2 using a Potter–Elvehjem homogenizer (6×800 rpm). The mem-
brane fraction obtained after centrifugation at 20000 rpm for 15 min was used in the binding 
experiments.  
[3H]Spiperone receptor binding assay. [3H]Spiperone (73.36 Ci mmol-1, Perkin Elmer 
LAS GmbH, Rodgau, Germany) binding was assayed in 1.0 mM EDTA, 4 mM MgCl2, 1.5 
mM CaCl2, 5 mM KCl, 120 mM NaCl, 25 mM Tris-HCl solution, pH 7.4, with rat caudate 
nuclei synaptosomal membranes (protein concentration 0.6 mg mL-1), at 37 °C for 10 min in a 
total volume of incubation mixture of 0.4 mL. The binding of the radioligand to 5-HT2 rec-
eptors was prevented by 50 mM ketanserin. The Ki values of the tested compounds were det-
ermined by competition binding at 0.2 nM of the radioligand and eight different concen-
trations of each compound (10-4–10-10 M). Nonspeciﬁc binding was determined in the pre-
sence of 10 µM spiperone. The reaction was terminated by rapid ﬁltration through Whatman 
GF/C ﬁlters, washed three times with 5.0 mL of ice-cold incubation buffer, and the retained 
radioactivity was measured in a 1219 Rackbeta Wallac scintillation counter (EG&G Wallac, 
Turku, Finland). Inhibition curve construction and statistical (Student’s t-test) analysis were 
performed by Graph-Pad Prism (GraphPad Software Inc). Hill slope coefficients were fixed to 
unity during the calculations.  
Computational study 
Docking simulations. The docking procedure was performed using Forecaster software.17 
The receptor model PDB code 6CM418 was used together with 2D structures of the ligands, 
prepared in ChemDraw.19 All structures were prepared in the software using default proce-
dures. Rigid receptor, flexible ligand docking was carried out. The obtained docking struc-
tures were examined and structures with the maximum number of receptor–ligand interactions 
were selected for further analysis. 
Binding poses metadynamics. The docking pose quality was assessed in terms of the 
fluctuations of the ligand RMSD (the root-mean-square deviation of atomic positions), and the 
persistence of important contacts between the ligand and the receptor (Metadynamics Binding 
PoseScore and Metadynamics Binding Persistence) using Desmond software and default para-
meters.20 One docking pose with the lowest RMSD and best overall score was selected for 
molecular dynamics (MD) simulations. 
Construction of a protein–membrane system for molecular dynamics. The protein pro-
tonation state was adjusted using the Schrodinger Protein Preparation module, at physiological 
pH (pH 7.4). The prepared protein was embedded into a POPC membrane bilayer using the 
Desmond system builder module,20 and oriented according to data from the Orientations of Pro-
teins in Membranes (OPM) server.21 The embedded protein was solvated with TIP3P explicit 
water model, and the system was neutralized via counter ions and a salt solution of 0.15 M 
KCl. In this way, systems were obtained that were subjected to membrane relaxation protocol.20 
MD simulations. Molecular dynamics (MD) simulations of the system were performed 
using Schrodinger Desmond software packages.20 OPLS 2003 forcefield22 was used to calcul-
ate the interactions between all the atoms. For the calculation of long-range coulombic inter-
actions, the particle–mesh Ewald (PME) method was used, with a cut-off radius of 9 Å for 
short-range van der Waals (vdW) and electrostatic interactions.  
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During the course of the simulation, a constant temperature of 310 K and a pressure of 
1.01235 bar were maintained, using a Nose–Hoover thermostat,23 and the Martyna–Tobias– 
–Klein method.24 Time increments of 2.0 fs were used in the simulations. Finally, 100 ns MD 
simulation for the each ligand– DRD2 complex was performed and the collected trajectory 
frames used in the MD analysis to quantify the protein–ligand interactions. 
RESULTS AND DISCUSSION 
Compounds 5a–n were synthesized according to Scheme 1. The synthesis 
started with N-(2-methoxyphenyl)piperazine (1) that was alkylated with a series 
of homologous bromo-esters 2a–g, providing N-alkylated products 3a–g. Count-
erpart diamines 4a–c were obtained by reduction of the corresponding 2-nitro 
precursors, using Raney-Ni and hydrazine hydrate under conditions described in 
earlier publications.25,26 Microwave assisted condensation of piperazines 3a–g 
and diamines 4a–c, under forcing, strongly acidic conditions, secured the desired 
benzimidazoles 5a–n. 
 
Scheme 1. Synthesis of the compounds 5a–n n = 1–7 for compounds 2a–g and 3a–g; ethyl 
esters of the general structure 2 were used in the synthesis of 3b, 3c, 3e and 3f; 4a 
(R = H); 4b (R= OMe); 4c (R= Cl); structures 5a–n are presented in Table I. 
DRD2 binding affinities of compounds 5a–5n were evaluated in vitro using 
[3H]spiperone as a standard dopaminergic radioactive ligand (Table I).27 
Molecular docking simulation of the herein described 2-{[4-(2-methoxyphe-
nyl)piperazin-1-yl]alkyl}-1H-benzo[d]imidazoles on D2DR was performed on 
the D2DR crystal structure published recently by Wang et al.15 They reported 
that the benzisoxazole moiety of risperidone interact with D2DR through 
Cys1183.36, Thr1193.37, Ser1975.46, Phe1985.47, Phe3826.44, Phe3906.52 and 
Trp3866.48 in the orthosteric binding site (OBS). OBS of D2DR is defined by the 
amino acid side chains of helices III, V and VI and also harbour Asp1143.32. 
Asp1143.32 forms an essential salt-bridge with protonated piperidine nitrogen of 
risperidone molecule. In addition D2DR has a secondary binding pocket, ext-
ended binding pocket (EBP), that encloses the tetrahydropyridopyrimidinone 
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moiety of risperidone. EBP is bordered by the extracellular part of TM VII con-
sisting of an extracellular loop 1 (EL1) and the junction of helices I, II and VII.15 
TАBLE I. Chemical structures and DRD2 binding constants of 2-{[4-(2-methoxyphenyl)pip-
erazin-1-yl]alkyl}-1H-benzimidazoles (5a–n); DRD2 binding constants (Ki) were determined 
in a [3H]spiperone displacement assay. The values are the mean of three independent 
experiments realized in triplicate, performed at eight competing ligand concentrations 
 
Ligand n R Ki ± SEM /nM 
5a 1 H >1000 
5b 2 H >1000 
5c 3 H >1000 
5d 4 H >1000 
5e 5 H 24±1 
5f 6 H 16±2 
5g 7 H >1000 
5h 4 OCH3 124±5 
5i 5 OCH3 12±3 
5j 6 OCH3 76±8 
5k 7 OCH3 >1000 
5l 4 Cl 109±9 
5m 5 Cl 25±3 
5n 6 Cl 102±3 
Molecular docking simulations on the binding of 2-{[4-(2-methoxyphenyl)-
piperazin-1-yl]alkyl}-1H-benzimidazoles into the crystal structure of DRD2 
show that the (2-methoxyphenyl)piperazine moiety occupies DRD2 OBS, and 
interacts with Asp1143.32, Cys1183.36, Trp3866.48 and Phe3906.52, while the 
benzimidazole part interacts with Leu942.64, Ile184EL2,Trp100EL1, Phe3896.51, 
Thr4127.39 and Tyr4087.35 in the EBP (Fig. 1). 
Compounds with optimal linker length (five or six methylene groups in the 
linker) allow the benzimidazole moiety to reach EBP and to interact with 
Leu942.64, Trp100EL1, Phe3896.51, Thr4127.39 and Tyr4087.35 (Fig. 2). Com-
pounds with shorter linker (5a–d) do not reach into the EBP, while ligands with 
seven methylene groups in the linker (5g and 5k) are too long to fit optimally 
into the D2DR binding cleft and protrude into the extracellular space.  
These results are in agreement with experimental data: compound 5d (with a 
4 methylene groups linker) has affinity of over 1000 nM, while compounds 5e 
and 5f (with 5 and 6 methylene groups linker, respectively) have 24 and 16 nM, 
respectively. Compound 5g shows a sharp drop in affinity because of the length 
of the linker, which cannot be accommodated in the DRD2 bind cleft.  
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Fig. 1. Docking of ligand 5i to DRD2 is presented. View of the interactions between the 3D 
model of the DRD2 binding site and ligand 5i. The images show only the key amino acid 
residues of the receptor binding pocket. Figures (side view–left and top view–right) show 
docking of 5i viewed from different angles. Binding site ligand accessible surface 
is shown in the top view. 
In series of compounds substituted with methoxy and chloro groups, the 
highest DRD2 affinity was obtained with compounds 5i and 5m. Linker with 5 
methylene groups facilitates optimal positioning of substituted benzimidazole 
part in the receptor EBP (Fig. 1). Shorter linkers, as it is obvious in series 5h–k 
and 5l–n, lead to decrease in receptor affinity due to sub-optimal placement of 
benzimidazole part in regard to the interacting residues Trp100EL1 and Tyr4087.35.  
To test the stability of obtained docking poses, MD simulations of the DRD2 
and selected ligands were performed on inactive receptor state for 100 ns for 
each ligand. Obtained trajectories were analyzed with focus on the residues that 
form OBS and EBP (Table S-I of the Supplementary material). 
Most of the receptor–ligand interactions in OBS, observed in molecular 
docking simulations, persisted for a significant portion of MD run (>20 % total 
simulation time). Compounds with significant DRD2 affinity (5e–f, 5h–j and 5l–n) 
had a salt bridge between the protonated piperazine nitrogen of the ligand and 
Asp1143.32 of DRD2 preserved for more than 79–84 % of the simulation time. 
Additional interactions in OBS are aromatic interaction with Cys1183.36 (32–75 
% of the simulation time), and edge-to-face interactions with Trp3866.48 (76–98 
% of the simulation time) and Phe3906.52 (20–49 % of the simulation time). In 
the EBP, significant interactions are aromatic interactions (edge-to-face type) 
with Trp100EL1, Phe3896.51 and Tyr4087.35. Compounds 5e, 5f, 5i and 5m form 
an additional hydrogen bond with Thr4127.39.  
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Fig. 2. Results of docking simulations for ligand 5e (A), 5f (B), 5i (C) and 5m (D) are pre-
sented. Schematic representation of the best docking pose for all ligands are provided. For 
clarity, only amino acid residues in close contact with ligands are shown. Solid lines represent 
aromatic, while dotted lines represent electrostatic interactions. 
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CONCLUSIONS 
Molecular docking and MD simulation provide important information that 
explains how the receptor–ligand complexes are formed. High affinity 2-{[4-(2- 
-methoxyphenyl)piperazin-1-yl]alkyl}-1H-benzimidazoles must simultaneously 
occupy both OBS and EBP.  
To establish key interactions both in OBS (salt bridge formation and aro-
matic interactions) and EBP (aromatic interactions and hydrogen bond form-
ation), the ligands should have a linker of five or six methylene groups. Linker 
flexibility and substituent size in the benzimidazole moiety determine ligand 
positioning inside the EBP and brings it in close contact with Trp100EL1 and 
Tyr4087.35, which are key interacting residues. Additionally, as can be concluded 
from the results of molecular dynamics, the affinity of the arylpiperazine ligands 
benefit greatly from possible formation of interactions of the arylpiperazine part 
of ligands with Thr4127.39 in EBP.  
It is clear that both Trp100EL1 and Tyr4087.35 can form aromatic interactions 
and/or hydrogen bonds. To establish the exact nature of interactions in EBP, 
modification of presented ligands, in terms of target synthesis of the compounds 
which can strictly form only one of these interactions, represent a guideline for 
further investigation. 
SUPPLEMENTARY MATERIAL 
Analytical and spectral data for the synthesized compounds, as well as additional results, 
are available electronically from http://www.shd.org.rs/JSCS/, or from the corresponding 
author on request. 
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И З В О Д  
СИНТЕЗА НОВИХ ДЕРИВАТА 2-(ПИПЕРАЗИНО-1-ИЛ-АЛКИЛ)-1Н-БЕНЗИМИДАЗОЛА 
И ПРОУЧАВАЊЕ ИНТЕРАКЦИЈА СА Д2 ДОПАМИНСКИМ РЕЦЕПТОРОМ 
ЈЕЛЕНА З. ПЕЊИШЕВИЋ1, ДЕАНА Б. АНДРИЋ2, ВЛАДИМИР Б. ШУКАЛОВИЋ1, ГОРАН М. РОГЛИЋ2, 
ВУКИЋ ШОШКИЋ3 и СЛАЂАНА В. КОСТИЋ-РАЈАЧИЋ1 
1ИХТМ-Центар за хемију, Универзитет у Београду, Његошева 12, 11000 Београд, 2Хемијски 
факултет, Универзитет у Београду, Студентски трг12–16, 11000 Београд и 3Orgentec GmbH, 
Carl-Zeiss-Str. 49, 55129 Mainz, Germany 
У овом раду је презентована синтеза 14 нових арилпиперазина и одређен је њихов 
афинитет везивања за Д2 допамински рецептор (DRD2) тестовима компетиције са 
[3H]спипероном. По својој хемијској структури ова једињења представљају супституисане 
бензимидазоле повезане са N-(2-метоксифенил)пиперазинским делом, линкерима разли-
читих дужина. У циљу испитивања лиганд-рецептор интеракција и особина везивног места 
DRD2, урађена је докинг анализа новосинтетисаних једињења и симулација молекулске 
динамике, користећи кристалну структуру рецептора. Резултати добијени у овом раду 
указују да арилпиперазини високог афинитета остварују интеракције у ортостерном везив-
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ном месту и у екстензији ортостерног места везивања DRD2 и да стога треба да поседују 
линкер оптималне дужине, од 5 или 6 метиленских група. 
(Примљено 29. октобра, ревидирано 3. децембра, прихваћено 4. децембра 2018) 
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